Skip to main content

Table 5 Selected clinical trials targeting cell surface proteins in triple negative breast cancer

From: Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications

Trial

Target

Treatment vs. control arm

Phase

Setting

Key results

(Treatment vs. control)

Strategies targeting cell surface receptors

IMMU-132–01 [153]

Trop-2 inhibitor

(Sacitizumab govitecan-hziy)

Sacitizumab govitecan-hziy

I/II

Heavily pretreated metastatic TNBC

Objective response rate 33.3%

Median PFS 5.5 months

ASCENT [154]

Trop-2 inhibitor

(Sacitizumab govitecan-hziy)

Sacitizumab govitecan-hziy vs. Chemotherapy

III

Heavily pretreated metastatic TNBC

Median PFS

5.6 vs. 1.7 months

HR 0.41 (95%CI 0.32–0.52; P < 0.001)

NCT01969643

LIV-1

Inhibitor

(ladiratuzumab vedotin)

Ladiratuzumab vedotin

I

Advanced breast cancer

Ongoing

Interim results: objective response rate of 32%

NCT03310957

LIV-1

Inhibitor

(ladiratuzumab vedotin)

 + PD1 inhibitor (pembrolizumab)

Ladiratuzumab vedotin

 + 

pembrolizumab

I/II

Advanced TNBC

Ongoing

Primary endpoint is objective response rate

Secondary endpoints include PFS and OS

DESTINY-Breast04

[162]

Trastuzumab-deruxtecan

(T-Dxd)

Trastuzumab-deruxtecan

vs

Chemotherapy (physician’s choice

III

Pretreated Her2-low, unresectable and/or metastatic breast cancer

Median PFS

9.9 vs. 5.1 months

HR 0.51 (95%CI 0.40–0.64; P < 0.001)

  1. Abbreviations: PFS progression free survival, OS overall survival, HR hazard ratio, CI confidence interval, TNBC triple negative breast cancer